LMTK3

LMTK3 as prognostic marker for ovarian cancer and TTX335o, award-winning drug candidate with tumor-killing activity, presented as game-changing treatment for women WALTHAM, Mass.--(BUSINESS WIRE)-- Temple Therapeutics, a biotechnology company pioneering a female-focused precision medicine approach, presented new in vitro and in vivo data on TTX335o, the first drug candidate from the company’s platform that won the Eurostar Eureka peer-reviewed grant process in 2019 for ovarian cancer, and the novel ovarian cell target, lemur tyrosine kinase 3 (LMTK3). The new data was provided at a poster presentation at the American Association of Cancer Research (AACR) Annual Meeting, which took place on April 14-19, 2023 in Orlando. “While survival rates for ovarian cancer are creeping up to the 50% level, it is clear that the vast majority of women are diagnosed too late,” said Sanj Singh, CEO of Temple Therapeutics. “It has been referred to as the silent killer by some, and others have described it as the neglected or ignored killer. Despite its lethality as the most dangerous gynecological cancer, the field has been sparsely researched. We are changing that. As we recognize World Ovarian Cancer Day today, we can do better. Our sisters, aunts, spouses, friends, co-workers, mothers, and grandmothers are affected.” TTX335o is based on the breakthrough discovery of LMTK3 and its mechanism of action. Increased levels of LMTK3 have been shown to affect the transcription of genes promoting DNA repair, cell viability, and tumorigenesis which activates cell death pathways specific to cancer cells without harming normal cells. Preclinical data presented at AACR 2023 included: LMTK3 protein was detected in 98% of ovarian cancer tissues collected from 204 patients in various stages and major histology and localized in the nucleus of health cells and in the cytoplasm of tumor cells. Risk of death among ovarian cancer patients with more cytoplasmic than nuclear LMTK3 levels was particularly high during the first year after diagnosis. This suggests cytoplasmic LMTK3 expression correlates with poor survival which serves as a potential prognostic marker for ovarian cancer patient outcomes (p<.01). TTX335o specifically targets apoptosis, a major determinant in uncontrolled cell growth in ovarian cancer through a novel integrin (αV/β1), monomeric myeloperoxidase (mMPO), and LMTK3 signaling pathways. Knocking down LMTK3 also induced cell death in ovarian cancer, and more importantly, did not harm normal cells. In vitro and in vivo studies seem to validate LMTK3 as a specific target and predictor of clinical outcomes in ovarian cancer. Both nuclear and cytoplasmic LMTK3 expressions correlated with tumor grade and patient survival in cancers such as breast and colorectal cancer. The clinical significance of the LMTK3 gene was tested from 204 early-stage (stage I-II) ovarian cancer patients of all major subtypes. Results from this study revealed a higher cytoplasmic to nuclear localization of LMTK3 correlated with worse overall survival (P<0.01). More importantly, engineered novel target-specific molecules, collectively known as TTX335o, significantly induced ovarian cancer cell death. Strikingly, TTX335o molecules are also effective in cells resistant to chemotherapy (e.g., docetaxel or cisplatin) as in sensitive cells. “The discovery of this novel target almost five years ago was surprising and exciting because we thought, what if this could be an early detection biomarker,” said Dr. Ghassan Saed, Inventor and Lead Researcher and Associate Professor of Gynecology Oncology at Wayne State University and Karmanos Cancer Center in Michigan. “Dr. Helou at Sahlgrenska Cancer Center screened the target across 204 Stage I-II ovarian cancer patient samples and saw firsthand the correlation data of expression of the target and poor prognosis. We knew then this may be a game changer for ovarian cancer because it was present in all major subtypes. We saw the potential for a novel biomarker and an associated target. We developed TTX335o to specifically target LMTK3 pathways that kill tumors without harming normal cells, even at high doses.” “Treatment with TTX335o and other modalities, like siRNA, significantly induced the killing of both chemosensitive and chemoresistant ovarian cancer cells without affecting normal cells in vitro,“ said Anna Portela, CEO of Xenopat, a spin-off of the Catalan Institute of Oncology (ICO), the Bellvitge Biomedical Research Institute (IDIBELL), and the Bellvitge University Hospital (HUB). “Moreover, we observed this killing as synergistic with both Cisplatin and Taxotere treatment in vitro. We used an A2780 cell line-derived orthotopic xenograft mouse model of ovarian cancer to test the efficacy of specific TTX335o in vivo. Strikingly, TTX335o 20 mg/kg IV dose given in the same dosing schedule and duration as cisplatin showed a 35% tumor reduction. More importantly, in vivo safety studies showed no signs of toxicity of TTX335o, even at a very high dose of 40 mg/kg. With molecule, dose, and schedule optimization in ongoing experiments, we could expect a higher efficacy.” “We have generated a substantial amount of preclinical data demonstrating TTX335o is unlike any other targeted therapy for ovarian cancer or approach,” said Dr. Neil Sankar, Chief Medical Officer at Temple Therapeutics. “The addition of a companion diagnostic for early detection, therapeutic impact, and disease progression injects much-needed hope for ovarian cancer patients. Earlier diagnosis and intervention improve patient outcomes. It seems that this target is agnostic across the major histological subtypes which helps to serve the 80% of ovarian cancer patients who do not have the BRCA genes (BReast CAncer).” Follow the World Ovarian Cancer Coalition on Twitter @ovariancancerco and #NoWomanLeftBehind. The AACR 2023 poster is available upon request at info@templerx.com. About Temple Therapeutics Temple Therapeutics is a clinical-stage, privately held biotechnology company pioneering a female-focused precision medicine approach for the discovery, development, and commercialization of novel therapeutics and companion diagnostics for early detection and treatment of profibrotic gynecological and related disorders. Temple’s mission is inspired by a belief that medical progress must be available to all, serving the underserved women’s health population and providing access to effective and safe treatment options through our focus on research and new health technologies. Temple Therapeutics’ current pipeline spans endometriosis, ovarian cancer, and related disorders of abdominal tissue fibrosis. With the goal of becoming a leading Ob/Gyn biopharma, our vision is for a world in which gynecological health is destigmatized, early diagnostics lead to less invasive treatments, and healthcare is accessible and holistic—addressing physical, mental, and social well-being. For more information, visit and follow on LinkedIn. All trademarks recognized.

New York, NY, April 22, 2021 (GLOBE NEWSWIRE) -- Facts and Factors have published a new research report titled “Breast Cancer Treatment Market By Types (Invasive Lobular Carcinoma, Invasive Ductal Carcinoma, and Others), by Treatment (Surgery & Radiation Therapy, Targeted Therapy, Chemotherapy, Biologic Therapy, and Hormone Therapy), End Users (Private Pharmacies, and Hospital Pharmacies): Global and Regional Industry Perspectives, Comprehensive Analysis, and Forecasts, 2020 – 2026”. “According to the research report, the global Breast Cancer Treatment Market was estimated at USD 19.24 Billion in 2019 and is expected to reach USD 34.06 Billion by 2026. The global Breast Cancer Treatment Market is expected to grow at a compound annual growth rate (CAGR) of 8.5% from 2019 to 2026”. Breast Cancer Treatment Market: Key Market Insights Overview Post diagnosis, cancer therapy requires different procedures depending upon the form and severity of cancer. The cancer care market is increasing at a substantial pace due to the rise in the occurrence of cancer cases, growing knowledge among people about different stages, and availability of treatment of cancer. Breast cancer treatment relies on different factors, such as breast cancer origin, tumor size, and breast cancer phase, and cancer grade. Operations, radiation therapy, chemotherapy, hormone therapy, targeted therapy, and bone-led therapy are some of the most popular approaches used in the management of breast cancer. In 2012, breast cancer accounted for 11.9% of the estimated cases of cancer recorded and resulting in 5.22,000 deaths worldwide, according to GLOBOCA, a program of the World Health Organisation, which examined the frequency, death, and prevalence of important forms of cancer in countries. Request Your Free Sample Report of Breast Cancer Treatment Market @ (The free sample of this report is readily available on request). Our Free Sample Report Includes: (Note: The sample of this report is updated with COVID-19 impact analysis before delivery) Key Questions Answered in this Report 1) What were the pre and post-business impacts of COVID-19 on the Breast Cancer Treatment Market? 2) What is the market size, share of the Breast Cancer Treatment Market? 3) Who are the top market players in the Breast Cancer Treatment Market? 4) What will be the future market of the Breast Cancer Treatment Market? Key Offerings: Inquire more about this report before purchase @ (You may enquire a report quote OR available discount offers to our sales team before purchase.) Breast Cancer Treatment Market: Industry Major Market Players To know an additional revised 2020 list of market players, request a sample report: It is anticipated that the status of breast cancer as one of the world's most prevalent cancers is a major driver of the global market. With the diagnosis of breast cancer in patients worldwide, the patient's need for precise and timely care remains unrivaled. In addition, the clear pattern of continuing research and development by key players in breast cancer therapy will lead to the introduction in the coming years of advanced treatment. This trend towards new, innovative treatments such as personalized therapies and immunotherapies is projected to significantly boost global growth in the forecast period in both developed and emerging regions. Directly Purchase a copy of the report with TOC @ Increasing breast cancer, higher R&D spending, and progress in cancer biology The rising burden of breast cancer, higher R&D spending, progress in cancer biology, and pharmacology fostering drug discovery are some factors projected to drive market growth. Globocan estimated that about 2 261 419 new cancer cases worldwide were reported by 2020, accounting for approximately 11.7% of the existing cancer cases. Besides, the increased number of breast cancer therapy-associated clinical studies during the provisioning timeframe stimulated business demand. As an example, Lemur tyrosine kinase 3 (LMTK 3) has been identified as having an essential role in cell proliferation in breast cancer by University of Sussex researchers in November 2020. Also, the studies on LMTK3 related medicines will be furthered. Such advances could provide greater possibilities for breast cancer care. Thus the demand growth over the projected timeframe is likely to intensify. Several unsatisfactory patient needs for cancer care have stimulated research and development in breast cancer treatment. The global breast cancer care demand is driven by several reasons, such as increased cancer incidence, increasing political participation, and increasing support from numerous government and non-government organizations. Moreover, the worldwide breast cancer industry is driven by an ethical embrace of multiple therapies, such as radiation therapy, hormone therapy, and others for cancer and increasing populations of DNA vaccines. However, the global breast cancer therapy industry is restricted by lower visibility and high costs. Innovative, improved successful therapy could provide a fair chance for the breast cancer industry. Innovation is projected to offer Moreover, amid the high costs of R&D; there has been renewed investment in this sector by pharmaceutical firms. The demand for breast cancer care is projected to deliver the positive promise. Request Customized Copy of Report @ (We customize your report according to your research need. Ask our sales team for report customization.) COVID-19 Impact on the Global Breast Cancer Treatment Market The COVID-19 pandemic is anticipated to have both good and negative consequences for the pharmaceutical industry. During the early stages of the pandemic, some countries have enforced stringent national lockouts to prevent the transmission of coronavirus. This leads to a significant detrimental effect on the healthcare system, as patients' flow to the treatment environment has significantly decreased. Also, the effect was strengthened when certain rules indicated that non-essential or elective surgical treatments would be deferred or canceled. The COVID-19 pandemic has a small influence on this global market as it is a life-saving therapy for some patients. Simultaneously, there were certain consequences, such as limited progress, as proceedings were delayed until later in certain situations. Therefore, because of the COVID-19 pandemic, the world economy saw limited to limited growth. The elective process was delayed until the mid COVID-19 saw a decrease in revenue. The COVID-19 pandemic has had a major impact on the demand for optional medical equipment. With COVID-19 cases worldwide growing alarmingly, countries have mostly shut down their manufacturing plants that have negatively impacted producers of medical devices. Under an article from Mondaq, medical factories are heavily dependent on China to buy important components, raw materials, and complex medical products. China is the fourth-largest supplier of medical technology in the United States. However, the closure of Chinese facilities could instantly affect the industry. To Know COVID-19 Pre and Post Business Impact Analysis, Request a Free Report PDF Brochure: North America Region Dominates the Global Breast Cancer Treatment Market The world demand for breast cancer care is dominated by North America, followed by Europe. This is because the rate of cancer cases and the technical progress in the field is growing. Increasing patient groups, increasing government policies, rising economies, and healthcare standards are expected to be a cause for Asia's strong growth in the breast cancer industry. Increased R&D spending, massive patient population, and increased government support is a major driving force on the breast cancer industry in developing countries. Browse the full “Breast Cancer Treatment Market, By Types (Invasive Lobular Carcinoma, Invasive Ductal Carcinoma, and Others), By Treatment (Surgery & Radiation Therapy, Targeted Therapy, Chemotherapy, Biologic Therapy, and Hormone Therapy), End Users (Private Pharmacies, and Hospital Pharmacies): Global and Regional Industry Perspectives, Comprehensive Analysis, and Forecasts, 2020 – 2026” report at  The Global Breast Cancer Treatment market is segmented as follows: By Types: By Treatment: By End Users: Related Reports: Adult Day Care Services Market: Healthcare in IT Market: Digital Pathology Market: Sleeping Aids Market: Abdominal Stent Graft System Market: About Facts & Factors (FnF Research): Facts & Factors is a leading market research organization offering industry expertise and scrupulous consulting services to clients for their business development. The reports and services offered by Facts and Factors are used by prestigious academic institutions, start-ups, and companies globally to measure and understand the changing international and regional business backgrounds. Our client’s/customer’s conviction on our solutions and services has pushed us in delivering always the best. Our advanced research solutions have helped them in appropriate decision-making and guidance for strategies to expand their business. Follow Us LinkedIn: Follow Us Twitter: Contact Us: Facts & Factors USA: +1-347-989-3985 Email: sales@fnfresearch.com Web: Blog: